These Small-Cap Biotech Companies May Be the Most Undervalued on the Market Today

Reading Time: 2 minutes

INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.

Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Dr. Mark Swaim.

On a recent Price of Business show, Host Kevin Price interviewed Dr. Mark Swaim, Editor in Chief of BioPub.
According to a statement, “As the biotech sector is going through an extraordinary period of innovation, many companies will fall by the wayside, but what companies will succeed and where can investors find value? Dr. Mark Swaim, Founder and editor-in-chief, BioPub, a small-cap biotech investing website with a global following, discusses with the Price of Business about his top three biotech picks poised for a breakout in 2022.

“Swaim, an early advocate of some of the world’s leading biotechs before they were widely recognized with high stock valuations – (such as Aurinia Pharmaceuticals) will discuss his lead recommendations for 2022.  They include Achieve Life Sciences, Medicenna and NervGen Pharma:
  • Achieve Life Sciences (NASDAQ: ACHV) is advancing cytisinicline for smoking cessation and is likely to produce a drug superior to Chantix,” says Dr. Swaim.  “At one time, I was a large prescriber of Chantix but grew alienated by its extreme psychiatric risks.  Their agent has no such downsides and while smoking is abating in the west, it flourishes in the east.”
  • Medicenna (NASDAQ: MDNA) has a highly novel therapeutic that extends survival in glioblastoma multiforme cancer patients by 150%,” say Dr. Swaim. “They are advancing to market an idealized bespoke version of interkeukin 2 with no toxicity while enhancing the immune system.  This company is trading at 10% of proper valuation.”
  • NervGen Pharma Corp.’s (TSX-V: NGEN) (OTCQX: NGENF) is in the process of developing NVG-291, a clinical stage candidate to treat spinal cord injuries, multiple sclerosis and Alzheimer’s disease, with preclinical functional data in many disease models based on mechanisms including nervous system regeneration, remyelination, plasticity, as well as autophagy and innate immune modulation “NVG-291is a veritable pipeline in a drug, given new evidence from animal models and in vitro work that it may treat not only spinal cord injury with restoration of gait but also multiple sclerosis, traumatic brain injury, Alzheimer dementia, stroke, Havana syndrome, maybe even Parkinson’s disease,” says Dr. Swaim.
“Dr. Swaim served on the faculties of Duke University Medical Center, University of Texas MD Anderson Cancer Center and the McGovern Medical School of University of Texas in Houston. He was elected to fellowship in the American College of Physicians.”

LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:

The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).

Share This:

About kevin 1559 Articles
No articles on this site should be construed as the opinion of PriceofBusiness.com. Do your homework, get expert advice before following the advice on this or any other site.

Be the first to comment

Leave a Reply

Your email address will not be published.


*